PDCD1 and gastric cancer: For more efficient use of anti-PD-1/PD-L1 antibodies in GC patients, a standardized set of criteria is required regarding several factors such as the types of antibodies and staining methods to be used, and the cut-off level for positivity of PD-L1 expression in terms of both intensity and extent.